Given that dMMR patients appear to be susceptible to immunotherapy36 and Fn has been shown to enhance the efficacy of PD-L1 blockage in CRC through both in vivo and in vitro evidence37, the enrichment of Fn/Fa in dMMR CRC raises questions regarding their roles in treatment response. The gene discussed is FN1; the disease is colorectal carcinoma.